v3.25.4

License Agreements (Details) - USD ($) $ in Millions | 1 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Feb. 28, 2023 | Aug. 31, 2017 | Dec. 31, 2025
XOMA (US) LLC | Xoma License Agreement |  |  |  |
License Agreements |  |  |  |
Milestone Payments |  |  |  | $ 12.0
XOMA (US) LLC | Xoma License Agreement | After Clinical and Regulatory Milestones | Maximum |  |  |  |
License Agreements |  |  |  |
Maximum additional milestone payments |  |  |  | 185.0
XOMA (US) LLC | US Clinical Trial Rz358 (ersodetug) | Xoma License Agreement | Upon Regulatory Approval |  |  |  |
License Agreements |  |  |  |
Milestone closing payment |  |  |  | 25.0
XOMA (US) LLC | Phase 3 Clinical Trial RZ 402 | Xoma License Agreement |  |  |  |
License Agreements |  |  |  |
Milestone closing payment | $ 5.0 |  |  |
ActiveSite Pharmaceuticals, Inc | Clinical Trial Rz 402 | Development And License Agreement |  |  |  |
License Agreements |  |  |  |
Milestone Payments |  |  |  | 4.0
ActiveSite Pharmaceuticals, Inc | Clinical Trial Rz 402 | Development And License Agreement | Maximum |  |  |  |
License Agreements |  |  |  |
Maximum additional milestone payments |  |  |  | 42.5
ActiveSite Pharmaceuticals, Inc | Clinical Trial Rz 402 | Development And License Agreement | Scenario, Plan |  |  |  |
License Agreements |  |  |  |
Royalties percentage |  |  | 2.00% |
ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement |  |  |  |
License Agreements |  |  |  |
Milestone closing payment |  | $ 3.0 |  |
ActiveSite Pharmaceuticals, Inc | Phase 3 Clinical Trial RZ 402 | Development And License Agreement | Scenario, Plan |  |  |  |
License Agreements |  |  |  |
Milestone closing payment |  |  |  | $ 5.0

X
- Definition Represents the percentage of royalties. + References No definition available. + Details
Name: | rzlt_DevelopmentAndLicenseAgreementRoyaltiesPercentage
Namespace Prefix: | rzlt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount payments due upon completion of various milestones within agreement. + References No definition available. + Details
Name: | rzlt_MaximumMilestonePaymentsAmount
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone payment made during the period. + References No definition available. + Details
Name: | rzlt_MilestoneClosingPayment
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of milestone payments recognized. + References No definition available. + Details
Name: | rzlt_MilestonePayments
Namespace Prefix: | rzlt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=rzlt_ScenarioAfterClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_ClinicalTrialRz358Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=rzlt_ScenarioUponRegulatoryApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz402Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rzlt_ActivesitePharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_ClinicalTrialRz402Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rzlt_DevelopmentAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase2ClinicalTrialRz402Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |